- The Japanese Ministry of Health, Labor and Welfare approves GlaxoSmithKline (GSK) and Theravance's (THRX) Anoro Ellipta (umeclidinium/vilanterol) for the relief of various symptoms of chronic obstructive pulmonary diseases in patients who require the concurrent use of a long-acting inhaled muscarinic antagonist and a long-acting inhaled beta2 agonist.
- Anoro is a once-daily treatment comprised of two broncodilators. Umeclidinium is the muscarinic antagonist and vilanterol is the beta2 agonist.
- Under the terms of the companies' 2002 collaboration agreement, Theravance is obligated to pay Glaxo a milestone payment of $10M based on Japanese regulatory approval.
From other sites
at CNBC.com (Thu, 1:44AM)
Video at CNBC.com (May 11, 2015)
Video at CNBC.com (May 6, 2015)
Video at CNBC.com (Jan 23, 2015)
at CNBC.com (Jan 6, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs